GALECTIN THERAPEUTICS INC (GALT) Form 10-Q — Aug 14, 2026
Galectin Therapeutics reported Q2 2026 results with substantial doubt about its ability to continue as a going concern, holding $13.3 million in cash plus $10 million remaining under a chairman-provided credit line, which management says funds planned operations only through June 2027. Second-quarter net loss widened to $9.1 million ($0.14 per share) from $7.5 million a year earlier, while six-month net loss improved to $14.2 million from $17.2 million as operating cash burn halved to $6.3 million following completion of the NAVIGATE belapectin trial. The company has no revenue and states it has no plans or funding for another clinical trial. On July 31, 2026, Chairman Richard E.
Key figures
- Cash Position
- 13269000
- Shares Outstanding
- 100849644
- Debt maturity
- June 30, 2027
- Options outstanding
- 7033681
- Warrants outstanding
- 1550000
- Undrawn loc available
- 10000000
- Conversion floor price
- 3
- Derivative liabilities
- 6135000
- Blended conversion price
- 3.07
- Uihlein ownership actual
- 44.3%
- Debt conversion principal
- 91000000
- Rd expense six months 2025
- 9746000
- Rd expense six months 2026
- 4366000
- Debt conversion shares issued
- 34376167
- Debt conversion accrued interest
- 14806981
- Interest expense six months 2026
- 3992000
- Uihlein voting power incl warrants
- 49.3%
Price after filing
Close on the filing date to close N calendar days later (from $3.44). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.